Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants

Indian Journal of Hematology and Blood Transfusion

Volumn 28, Issue 3, 2012, Pages 129-143

  Agarwal, M B ^a   Verma, Subhash ^b   Mahapatra, Manoranjan ^c   Tripathi, A K ^d   Bhave, Abhay ^e   Deshpande, Anand ^f   Vora, Amit ^e   Dalal, Jamshed J ^g   Shah, A B ^h   Bichu, S ^a  

^a BOMBAY HOSPITAL   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d KING GEORGE'S MEDICAL UNIVERSITY   (India)

^e LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

^f P D HINDUJA NATIONAL HOSPITAL   (India)

^g Kokilaben Dhirubhai Ambani Hospital   (India)

^h SAIFEE HOSPITAL   (India)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; INR; Rivaroxaban; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CARBAMAZEPINE; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; KETOCONAZOLE; PANTOPRAZOLE; PHENOBARBITAL; PHENYTOIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAMPICIN; RIVAROXABAN; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVERSION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PATIENT ASSESSMENT; PATIENT PREFERENCE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREOPERATIVE CARE; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; RETREATMENT; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; STROKE; THROMBIN TIME;

EID: 84865355553     PISSN: 09714502     EISSN: 09740449     Source Type: Journal    
DOI: 10.1007/s12288-012-0167-6     Document Type: Review

References (33)

1. V Fuster LE Ryden DS Cannom, et al. 2006 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 e254 e257
2. RG Hart, et al. 2007 Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 857 867 17577005 (Pubitemid 351650486)
3. G Albers J Dalen A Laupacis, et al. 2001 Antithrombotic therapy in atrial fibrillation Chest 119 1948 2068 10.1378/chest.119.6.1948 (Pubitemid 32744958)
4. S Connolly S Yusuf J Camm, et al. 2006 Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation Lancet 367 1903 1912 16765759 10.1016/S0140-6736(06)68845-4 1:CAS:528:DC%2BD28XlsFCrsLg%3D (Pubitemid 43842067)
5. SPAF Investigators 1996 Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial Lancet 348 633 638 10.1016/S0140-6736(96)03487-3 (Pubitemid 26293807)
6. EM Hylek DE Singer 1994 Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 897 902 8172435 1:STN:280:DyaK2c3is1Chug%3D%3D (Pubitemid 24179151)
7. J van Ryn J Stangier S Haertter, et al. 2010 Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 1116 1127 20352166 10.1160/TH09-11-0758
8. Pradaxa® Summary of Product Characteristics, 2011. Boehringer Ingelheim
9. van Ryn J, Baruch L, Clemens A (2012) Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 125:417-420
10. MM Samama JL Martinoli L LeFlem, et al. 2010 Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 815 825 20135059 10.1160/TH09-03-0176 1:CAS:528:DC%2BC3cXls1ansro%3D
11. A Tripodi V Chantarangkul C Guinet, et al. 2011 The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study J Thromb Haemost 9 226 228 20942848 10.1111/j.1538-7836.2010.04106.x 1:CAS:528:DC%2BC3MXitFCqt7g%3D
12. A Tripodi 2011 Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? Thromb Haemost 105 735 736 21225100 10.1160/TH10-11-0718 1:CAS:528: DC%2BC3MXmt1WkurY%3D
13. AJ Camm 2010 ESC guidelines for the management of atrial fibrillation Eur Heart J 31 2369 2429 20802247 10.1093/eurheartj/ehq278
14. JW Eikelboom L Wallentin SJ Connolly M Ezekowitz JS Healey J Oldgren, et al. 2011 Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) Circulation 123 2363 2372 21576658 10.1161/CIRCULATIONAHA.110.004747 1:CAS:528: DC%2BC3MXntVersbw%3D
15. MV Huisman, et al. 2012 Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice Thromb Haemost 107 5 838 22318514 10.1160/TH11-10-0718 1:CAS:528: DC%2BC38XosFaqtL8%3D
16. Winkle RA et al (2012) The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. doi: 10.1111/j.1540-8167. 2011.02175
17. H Calkins J Brugada R Cappato, et al. 2012 HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design Heart Rhythm 9 4 632 22386883 10.1016/j.hrthm.2011.12.016
18. Boehringer Ingelheim. Pradaxa® Product Monograph (India) (2012)
19. R Nagarakanti, et al. 2011 Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 131 136 21200007 10.1161/CIRCULATIONAHA.110.977546 1:CAS:528:DC%2BC3MXnsVSntg%3D%3D
20. DM Monroe M Hoffman JA Oliver, et al. 1997 Platelet activity of high-dose factor VIIa is independent of tissue factor Br J Haematol 99 542 547 9401063 10.1046/j.1365-2141.1997.4463256.x 1:CAS:528:DyaK2sXnvF2mu70%3D (Pubitemid 27519853)
21. MT Sartori S Imbergamo E Zanon, et al. 2009 Effect of recombinant activated Factor VII in critical bleeding: clinical experience of a single center Clin Appl Thromb Hemost 15 628 635 19605376 10.1177/1076029609335909 1:CAS:528:DC%2BD1MXhsFGlsr%2FE
22. British Committee for Standards in Hematology Blood Transfusion Task force 2004 Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant Br J Hematol 126 11 28 10.1111/j.1365-2141.2004.04972.x (Pubitemid 38859478)
23. A Lubetsky, et al. 2003 Comparison of oral versus intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study Arch Intern Med 163 2469 2473 14609783 10.1001/archinte.163.20.2469 1:CAS:528:DC%2BD3sXpvVyisbY%3D (Pubitemid 37385789)
24. SJ Connolly, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
25. SJ Connolly, et al. 2010 Newly identified events in the RE-LY trial N Engl J Med 363 19 1875 1876 21047252 10.1056/NEJMc1007378 1:CAS:528: DC%2BC3cXhtl2ls7zF
26. Marinigh R, Lane DA, Lip GY (2011) Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57:1339-1348
27. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes, and Digestive and Kidney Diseases, 2006
28. AS Go EM Hylek Y Chang, et al. 2003 Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 2685 14645310 10.1001/jama.290.20.2685 1:CAS:528:DC%2BD3sXpsVakt78%3D (Pubitemid 37475596)
29. BF Gage AD Waterman W Shannon 2001 Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2864 11401607 10.1001/jama.285.22.2864 1:STN:280:DC%2BD3MzntFKgsQ%3D%3D
30. European Medicines Agency (2011) Xarelto. Summary of product characteristics. http://www.ema.europa.eu/. Accessed, 19th Dec 2011
31. European Medicines Agency (2012) Eliquis. Summary of product characteristics. http://www.ema.europa.eu/. Accessed, 1st April 2012
32. MR Patel KW Mahaffey J Garg G Pan DE Singer W Hacke G Breithardt JL Halperin GJ Hankey JP Piccini RC Becker CC Nessel JF Paolini SD Berkowitz KA Fox 2011 ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med. 365 883 891 21830957 10.1056/NEJMoa1009638 1:CAS:528:DC%2BC3MXhtFKhsLnI
33. CB Granger JH Alexander JJ McMurray RD Lopes EM Hylek M Hanna HR Al-Khalidi J Ansell D Atar A Avezum MC Bahit R Diaz JD Easton JA Ezekowitz G Flaker D Garcia M Geraldes BJ Gersh S Golitsyn S Goto AG Hermosillo SH Hohnloser J Horowitz P Mohan P Jansky BS Lewis JL Lopez-Sendon P Pais A Parkhomenko FW Verheugt J Zhu 2011 ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981 992 21870978 10.1056/NEJMoa1107039 1:CAS:528:DC%2BC3MXhtF2ms7rN